Relay Therapeutics, Inc.
corporate_fare Company Profile
Relay Therapeutics, Inc. (NASDAQ:RLAY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for RLAY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for RLAY spans 10-Q, 144, 424B5, 8-K.
Recent high-impact activity:
- Relay 10-Q: $848.6M Cash Into 2029, Q3 Loss $81.7M, ATM Upsized to $463M
- Relay Posts $848.6M Cash, Accelerates Breast Cancer Enrollment to Mid-2027
- Relay Therapeutics Hits Phase 3 Milestone in X-Chem Collaboration
- SVF Pauling (Cayman) Files to Sell 6M Shares of Relay Therapeutics (~$123M)
- Relay Therapeutics Upsizes ATM Program to $463M, Adding $213M in New Capacity
Financial Snapshot
Short Interest & Short Volume
20.72 days to coverFINRA reported short interest of 43,629,223 shares in RLAY as of the October 30, 2026 settlement, a 0.9% decrease from the prior period — about 20.7 days to cover at its recent average daily volume. On November 20, 2026, 62.4% of RLAY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for RLAY, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.
Authorized Shares Increased · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →